scispace - formally typeset
R

Roberta Winnick

Researcher at North Shore-LIJ Health System

Publications -  5
Citations -  771

Roberta Winnick is an academic researcher from North Shore-LIJ Health System. The author has contributed to research in topics: Rasagiline & Placebo. The author has an hindex of 5, co-authored 5 publications receiving 733 citations.

Papers
More filters
Journal ArticleDOI

A controlled trial of rasagiline in early Parkinson disease: The tempo study

Andrew Siderowf, +89 more
- 01 Dec 2002 - 
TL;DR: Rasagiline is effective as monotherapy for patients with early PD and the 2 dosages in this trial were both effective relative to placebo.
Journal ArticleDOI

Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.

Robert A. Hauser, +137 more
- 15 Mar 2009 - 
TL;DR: Compared to delayed start, early initiation of rasagiline provided long‐term clinical benefit, even in the face of treatment with other dopaminergic agents.
Journal ArticleDOI

Rasagiline improves quality of life in patients with early Parkinson's disease

Kevin M. Biglan, +88 more
- 01 May 2006 - 
TL;DR: Rasagiline improved QOL compared with placebo, and this QOL improvement appears to be accounted for primarily by the symptomatic benefit of rasagILine.
Journal ArticleDOI

Mutations in LRRK2 other than G2019S are rare in a north-American based sample of familial Parkinson's didease

Nathan Pankratz, +102 more
- 01 Dec 2006 - 
TL;DR: Although the G2019S mutation remains the most common mutation identified in familial PD patients, other mutations in LRRK2 are infrequent and only 1 of the 12 newly screened mutations, R1441C, was detected in a single family in the patient cohort.
Journal ArticleDOI

R1514Q substitution in Lrrk2 is not a pathogenic Parkinson's disease mutation

William C. Nichols, +207 more
- 15 Jan 2007 - 
TL;DR: Data suggest that the R1514Q variant is not a pathogenic LRRK2 mutation, and it is imperative that the causative nature of any newly identified genetic variant be determined before it is included in any panel for diagnostic testing.